Introduction: Secukinumab is a human monoclonal antibody that selectively targets and
neutralizes interleukin (IL)-17A, a cytokine that is normally involved in mucocutaneous …

The development of several highly effective biologic drugs in the past decade has
revolutionized the treatment of moderate-to-severe plaque psoriasis. With increased …

Background Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has
demonstrated efficacy and safety in patients with moderate to severe plaque psoriasis …

Secukinumab is a human monoclonal antibody that selectively targets interleukin-17A and
has been demonstrated to be highly efficacious in the treatment of moderate to severe …

Our ability to successfully treat patients with moderate to severe psoriasis has improved
significantly over the last several years with the development of more targeted therapies. IL …

В обзоре обсуждается возможность применения терапевтической стратегии «лечение
до достижения цели»(Т2Т) при псориазе, а также анализируются ключевые факторы …

Background: Major advances have been made in the understanding of the pathophysiology
of psoriasis. Objectives: The authors review the role of interleukin (IL) 17 in the pathogenesis …

Background: In January 2015, US FDA approved secukinumab, a human interleukin-17A (IL-
17A) antagonist, for the treatment of plaque psoriasis. Objective: To provide unbiased drug …

Introduction: The immunopathogenesis of psoriasis has led to the discovery and
development of several promising treatment options for psoriasis, including those that target …

Introduction: Psoriasis is a chronic condition whose therapeutic armamentarium is
increasingly being discussed, particularly when compared to past decades. The use of …